ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1475

Can the Use of the Serum Anti-PLA2R Antibody Negate the Need for a Renal Biopsy in Primary Membranous Nephropathy?

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Ragy, Omar Sherin, Manchester Metropolitan University, Manchester, Greater Manchester, United Kingdom
  • Rautemaa, Vilma, Manchester Metropolitan University, Manchester, Greater Manchester, United Kingdom
  • Kanigicherla, Durga Anil K, Manchester Metropolitan University, Manchester, Greater Manchester, United Kingdom
  • Hamilton, Patrick, Manchester Metropolitan University, Manchester, Greater Manchester, United Kingdom

Since the emergence of the anti-PLA2R antibody test, nephrology practice has not changed dramatically, and most nephrologists are still relying on performing a kidney biopsy in diagnosing membranous nephropathy. In this study, we sought to examine how anti-PLA2R antibody tests using ELISA can be utilized in clinical practice.


We have conducted a retrospective analysis for 187 patients between 2003 and 2020 correlating their renal biopsy findings with their anti-PLA2R antibody test when performed. We have recorded all patient’s demography, urine protein creatinine ratios, serum albumin, and treatment commenced whether using RAS blockade or immunosuppression treatment.
Using a statistical analysis model, we have calculated the positive and negative predictive values of the anti-PLA2R ab test carried out during that period.


The mean levels of anti-PLA2R antibody titer in primary membranous nephropathy were 217 RU/ml, whereas the mean level was only 3 RU/ml for both secondary membranous nephropathy and other diagnoses. The majority of our cohort who had a positive anti-PLA2R antibody test had a confirmed renal biopsy diagnosis of primary membranous nephropathy with a PPV of 97.3%. Also, we found that the test sensitivity was 75.5%. On the other hand, we found that the NPV was 79.8% and the specificity was 97.8% at a level of >20 RU/ml


The anti-PLA2R antibody test is a highly specific test for diagnosing membranous nephropathy. Experience from our center supported by some evidence from the literature suggests that we can rely solely on a positive test without the need to perform a renal biopsy. More prospective trials are required to further validate that notion.


  • Private Foundation Support